Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924
[<sup>18</sup>F]AlF-NOTA-SC exhibited CXCR4-specific uptake in vitro and in vivo, with fast and persistent tumor accumulation, making it a strong candidate for clinical translation as an <sup>18</sup>F-alternative to [<sup>68</sup>Ga]PentixaFor.
Authors
- Christopher Cawthorne (ORCID: https://orcid.org/0000-0002-5975-0354)
- Wim Vanduffel (ORCID: https://orcid.org/0000-0002-9399-343X)
- Dominique Schols (ORCID: https://orcid.org/0000-0003-3256-5850)
- Tom Van Loy (ORCID: https://orcid.org/0000-0003-2524-7264)
- Christophe M. Deroose (ORCID: https://orcid.org/0000-0002-6080-1577)
- Frederik Cleeren (ORCID: https://orcid.org/0000-0002-3692-1608)
- Michel Koole (ORCID: https://orcid.org/0000-0001-5862-640X)
- Guy Bormans (ORCID: https://orcid.org/0000-0002-0335-7190)
- Sofie Celen (ORCID: https://orcid.org/0000-0002-6742-7469)
- M. SPAHN
Institutions
- Rega Institute for Medical Research (BE)
- KU Leuven (BE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1007/s00259-024-07025-w
- Citations
- 8
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Fonds Wetenschappelijk Onderzoek
- Onderzoeksraad, KU Leuven
- Stichting Tegen Kanker